Skip to main content
SpringerLink
Log in

Small B-cell lymphocytic lymphoma and chronic lymphocytic leukemia

  • Chapter
  • First Online:
Management of Lymphomas: A Case-Based Approach

  • 726 Accesses

Abstract

A 72-year-old man with a history of diabetes mellitus, hypertension, and hypercholesterolemia self-palpated a left submandibular lump in 2012. Complete blood count (CBC) in his internist’s office showed solitary leukocytosis (white count 22) with predominant lymphocytes for which he was referred to a hematologist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Muller-Hermlink HK, et al. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours. In Haematopoietic and Lymphoid Tissues. Lyon, France. IARC press, 2001: 95–96.

    Google Scholar 

  2. National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER). SEER clinical statistics review, 1975-2009. https://seer.cancer.gov/archive/csr/1975_2009_pops09/. Accessed March 7, 2017.

  3. Brown JR, Neuberg D, Phillips K, et al. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haem. 2008;143:361–368.

    Google Scholar 

  4. Strati P, Shanafelt T. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126:454–462.

    Google Scholar 

  5. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111: 5446–5456.

    Google Scholar 

  6. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015; 90: 447–460.

    Google Scholar 

  7. Lopez-Guerra M, et al. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia. 2015;29:96–106.

    Google Scholar 

  8. Rossie D. IX. Chronic lymphocytic leukaemia: new genetic markers as prognostic factors. Hematol Oncol. 2014;31:57–59.

    Google Scholar 

  9. [No authors listed]. Chemotherapeutic options in chronic lymphocytic leukemia: a metaanalysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Institute. 1999;91:861–868.

    Google Scholar 

  10. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378–4384

    Google Scholar 

  11. Fischer K, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–3566.

    Google Scholar 

  12. Fischer K, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209–3216.

    Google Scholar 

  13. Rai KR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757.

    Google Scholar 

  14. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001; 98:2319–2325.

    Google Scholar 

  15. Hallek M, Eichhorst BF. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J. 2004;5:S20–S30.

    Google Scholar 

  16. Bosch F, Ferrer A, LĂ³pez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119:976–984.

    Google Scholar 

  17. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Hematol J. 2006;107:885–891.

    Google Scholar 

  18. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007; 25: 793–798.

    Google Scholar 

  19. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–239.

    Google Scholar 

  20. Reynolds C, Di Bella N, Lyons RM, et al. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs. 2012;30:1232–1240.

    Google Scholar 

  21. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000; 96:2723–2729.

    Google Scholar 

  22. Montillo M, Tedeschi A, O'Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer. 2003;97:114–120.

    Google Scholar 

  23. Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006;108: 473–479.

    Google Scholar 

  24. Tam CS, Keating MJ. Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence? Leuk Lymphoma. 2013;54:934–939.

    Google Scholar 

  25. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376:1164–1174.

    Google Scholar 

  26. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–215.

    Google Scholar 

  27. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–1765.

    Google Scholar 

  28. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498–503.

    Google Scholar 

  29. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood. 2014;124:19.

    Google Scholar 

  30. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–1755.

    Google Scholar 

  31. Hillmen P, Robak T, Janssens A, et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the Phase III study Complement 1 (OMB110911). Blood. 2013;122:528.

    Google Scholar 

  32. Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124:2196–2202.

    Google Scholar 

  33. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.

    Google Scholar 

  34. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567–1574.

    Google Scholar 

  35. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891–3897.

    Google Scholar 

  36. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561.

    Google Scholar 

  37. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616–5623.

    Google Scholar 

  38. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.

    Google Scholar 

  39. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

    Google Scholar 

  40. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15: 48–58.

    Google Scholar 

  41. Siddiqi T, Rosen S. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation. Oncology (Williston Park). 2015;29:299–308.

    Google Scholar 

  42. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.

    Google Scholar 

  43. O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–1418.

    Google Scholar 

  44. Burger JA, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373: 2425–2437.

    Google Scholar 

  45. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406–3413.

    Google Scholar 

  46. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397.

    Google Scholar 

  47. Furman RR, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.

    Google Scholar 

  48. Coutre SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779–2786.

    Google Scholar 

  49. Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.

    Google Scholar 

  50. O’Brien SM, et al. A phase 2 study of idelalisib plus rituximab in treatment-naĂ¯ve older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–2694.

    Google Scholar 

  51. Channan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343–5349.

    Google Scholar 

  52. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778.

    Google Scholar 

  53. Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010;51:85–88.

    Google Scholar 

  54. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291–5297

    Google Scholar 

  55. Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;13:584–591.

    Google Scholar 

  56. Porter DL, Levine Bl, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–733.

    Google Scholar 

  57. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.

    Google Scholar 

  58. Porter DL. Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. Blood. 2013;122:4162.

    Google Scholar 

  59. Jain N. Nivolumab combined with ibrutinib for CLL and Richter transformation: a Phase II trial. Blood. 2016;128:59.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duarte, USA

    Tanya Siddiqi & Steven T. Rosen

Authors
  1. Tanya Siddiqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven T. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. City of Hope Hospital, Duarte, California, USA

    Jasmine Zain

  2. Toni Stephenson Lymphoma Center, City of Hope Hospital, Duarte, California, USA

    Larry W. Kwak

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Siddiqi, T., Rosen, S.T. (2017). Small B-cell lymphocytic lymphoma and chronic lymphocytic leukemia. In: Zain, J., Kwak, L. (eds) Management of Lymphomas: A Case-Based Approach. Adis, Cham. https://doi.org/10.1007/978-3-319-26827-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26827-9_4

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-26825-5

  • Online ISBN: 978-3-319-26827-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation